{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:20:26Z","timestamp":1779146426568,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30-CA200345"],"award-info":[{"award-number":["F30-CA200345"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5-K23-CA157728-05"],"award-info":[{"award-number":["5-K23-CA157728-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["CI-64-12"],"award-info":[{"award-number":["CI-64-12"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011485","name":"North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["NCI 5U10CA181009"],"award-info":[{"award-number":["NCI 5U10CA181009"]}],"id":[{"id":"10.13039\/100011485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10549-018-4852-5","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T01:13:57Z","timestamp":1529889237000},"page":"637-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases"],"prefix":"10.1007","volume":"171","author":[{"given":"Amanda E. D.","family":"Van Swearingen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marni B.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison M.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Sambade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Hoyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Neil","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heejoon","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Claire","family":"Dees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyman","family":"Muss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Zagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirali","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Ryan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Keith","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisle","family":"Nabell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-4074","authenticated-orcid":false,"given":"Carey K.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"4852_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138:241\u2013256. \n                    https:\/\/doi.org\/10.5858\/arpa.2013-0953-SA","journal-title":"Arch Pathol Lab Med"},{"key":"4852_CR2","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977. \n                    https:\/\/doi.org\/10.1002\/cncr.11436","journal-title":"Cancer"},{"key":"4852_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/jnci\/djn216","volume":"100","author":"B Gril","year":"2008","unstructured":"Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. JNCI J Natl Cancer Inst 100:1092\u20131103. \n                    https:\/\/doi.org\/10.1093\/jnci\/djn216","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4852_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/annonc\/mdu133","volume":"25","author":"SM Swain","year":"2014","unstructured":"Swain SM, Baselga J, Miles D, Im Y-H, Quah C, Lee LF, Cort\u00e9s J (2014) Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 25:1116\u20131121. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu133","journal-title":"Ann Oncol"},{"key":"4852_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/annonc\/mdp407","volume":"21","author":"A Niwinska","year":"2010","unstructured":"Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942\u2013948. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp407","journal-title":"Ann Oncol"},{"key":"4852_CR6","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1002\/cncr.25391","volume":"116","author":"A Niwinska","year":"2010","unstructured":"Niwinska A, Murawska M, Pogoda K (2010) Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 116:4238\u20134247. \n                    https:\/\/doi.org\/10.1002\/cncr.25391","journal-title":"Cancer"},{"key":"4852_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.07.017","author":"LA Mounsey","year":"2017","unstructured":"Mounsey LA, Deal AM, Keith KC, Benbow JM, Shachar SS, Zagar T, Dees EC, Carey LA, Ewend MG, Anders CK (2017) Changing natural history of HER2\u2013Positive breast cancer metastatic to the brain in the era of new targeted therapies. Clin Breast Cancer.","journal-title":"Clin Breast Cancer"},{"key":"4852_CR8","first-page":"923","volume":"30","author":"TM Zagar","year":"2016","unstructured":"Zagar TM, Van Swearingen AED, Kaidar-Person O, Ewend MG, Anders CK (2016) Multidisciplinary management of breast cancer brain metastases. Oncology 30:923\u2013933","journal-title":"Oncology"},{"key":"4852_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","volume":"15","author":"NU Lin","year":"2009","unstructured":"Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452\u20131459. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1080","journal-title":"Clin Cancer Res"},{"key":"4852_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot T, Romieu G, Campone M, Di\u00e9ras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga J-Y, Gon\u00e7alves A, Leheurteur M, Domont J, Gutierrez M, Cur\u00e9 H, Ferrero J-M, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64\u201371. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(12)70432-1","journal-title":"Lancet Oncol"},{"key":"4852_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ctrc.2016.03.005","volume":"7","author":"KC Keith","year":"2016","unstructured":"Keith KC, Lee Y, Ewend MG, Zagar TM, Anders CK (2016) Activity of Trastuzumab-Emtansine (Tdm1) in Her2-positive breast cancer brain metastases: a case series. Cancer Treat Commun 7:43\u201346. \n                    https:\/\/doi.org\/10.1016\/j.ctrc.2016.03.005","journal-title":"Cancer Treat Commun"},{"key":"4852_CR12","doi-asserted-by":"publisher","first-page":"e163-6","DOI":"10.1016\/j.clbc.2014.10.003","volume":"15","author":"R Kalsi","year":"2015","unstructured":"Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chumsri S (2015) Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clin Breast Cancer 15:e163-6. \n                    https:\/\/doi.org\/10.1016\/j.clbc.2014.10.003","journal-title":"Clin Breast Cancer"},{"key":"4852_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.breast.2015.06.002","volume":"24","author":"ST Wilks","year":"2015","unstructured":"Wilks ST (2015) Potential of overcoming resistance to HER2-targeted therapies through the PI3K\/Akt\/mTOR pathway. Breast 24:548\u2013555. \n                    https:\/\/doi.org\/10.1016\/j.breast.2015.06.002","journal-title":"Breast"},{"key":"4852_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 F, O\u2019Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap Y-S, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580\u2013591. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70138-X","journal-title":"Lancet Oncol"},{"key":"4852_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/bjc.2012.85","volume":"106","author":"A Gallardo","year":"2012","unstructured":"Gallardo A, Lerma E, Escuin D, Tibau A, Mu\u00f1oz J, Ojeda B, Barnadas A, Adrover E, S\u00e1nchez-Tejada L, Giner D, Ortiz-Mart\u00ednez F, Peir\u00f3 G (2012) Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:1367\u20131373. \n                    https:\/\/doi.org\/10.1038\/bjc.2012.85","journal-title":"Br J Cancer"},{"key":"4852_CR16","doi-asserted-by":"publisher","first-page":"R49","DOI":"10.1186\/bcr3150","volume":"14","author":"H Wikman","year":"2012","unstructured":"Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, M\u00fcller V, Westphal M, Pantel K (2012) Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res BCR 14:R49. \n                    https:\/\/doi.org\/10.1186\/bcr3150","journal-title":"Breast Cancer Res BCR"},{"key":"4852_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","volume":"11","author":"J Jing","year":"2012","unstructured":"Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720\u2013729. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0505","journal-title":"Mol Cancer Ther"},{"key":"4852_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature15376","volume":"527","author":"L Zhang","year":"2015","unstructured":"Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D (2015) Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527:100\u2013104. \n                    https:\/\/doi.org\/10.1038\/nature15376","journal-title":"Nature"},{"key":"4852_CR19","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/bcr3071","volume":"13","author":"B Adamo","year":"2011","unstructured":"Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK (2011) Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 13:R125. \n                    https:\/\/doi.org\/10.1186\/bcr3071","journal-title":"Breast Cancer Res"},{"key":"4852_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125\u2013132. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61134-9","journal-title":"Lancet"},{"key":"4852_CR21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993\u20131999. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.12.3588","journal-title":"J Clin Oncol"},{"key":"4852_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280. \n                    https:\/\/doi.org\/10.1200\/JCO.1990.8.7.1277","journal-title":"J Clin Oncol"},{"key":"4852_CR23","unstructured":"National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v 4.0. Available from \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"4852_CR24","doi-asserted-by":"publisher","first-page":"e0129280","DOI":"10.1371\/journal.pone.0129280","volume":"10","author":"X Zhao","year":"2015","unstructured":"Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, Salazar AH, Jo H, Soloway MG, Wilkerson MD, Parker JS, Yin X, Zhang G, Siegel MB, Rosson GB, Earp HS, Sharpless NE, Gulley ML, Weck KE, Hayes DN, Moschos SJ (2015) Combined targeted DNA sequencing in non-small cell lung cancer (NSCLC) using UNCseq and NGScopy, and RNA sequencing using UNCqeR for the detection of genetic aberrations in NSCLC. PLoS ONE 10:e0129280. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0129280","journal-title":"PLoS ONE"},{"key":"4852_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4852_CR26","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15:974\u2013986. \n                    https:\/\/doi.org\/10.1200\/JCO.1997.15.3.974","journal-title":"J Clin Oncol"},{"key":"4852_CR27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q","volume":"75","author":"MA Weitzner","year":"1995","unstructured":"Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151\u20131161","journal-title":"Cancer"},{"key":"4852_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579. \n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.3.570","journal-title":"J Clin Oncol"},{"key":"4852_CR29","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754\u20131760. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/btp324","journal-title":"Bioinformatics"},{"key":"4852_CR30","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup (2009) The sequence alignment\/map format and SAMtools. Bioinformatics 25:2078\u20132079. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/btp352","journal-title":"Bioinformatics"},{"key":"4852_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1751-0473-9-13","volume":"9","author":"G Tischler","year":"2014","unstructured":"Tischler G, Leonard S (2014) biobambam: tools for read pair collation based algorithms on BAM files. Source Code Biol Med 9:13. \n                    https:\/\/doi.org\/10.1186\/1751-0473-9-13","journal-title":"Source Code Biol Med"},{"key":"4852_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26:841\u2013842. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/btq033","journal-title":"Bioinformatics"},{"key":"4852_CR33","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/bioinformatics\/btu376","volume":"30","author":"LE Mose","year":"2014","unstructured":"Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS (2014) ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 30:2813\u20132815. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/btu376","journal-title":"Bioinformatics"},{"key":"4852_CR34","unstructured":"Picard. In: Picard. \n                    http:\/\/broadinstitute.github.io\/picard\n                    \n                  . Accessed 9 Nov 2017"},{"key":"4852_CR35","unstructured":"Garrison E, Marth G (2012) Haplotype-based variant detection from short-read sequencing. ArXiv12073907 Q-Bio"},{"key":"4852_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2105-15-18","volume":"15","author":"H Baier","year":"2014","unstructured":"Baier H, Schultz J (2014) ISAAC - InterSpecies Analysing Application using Containers. BMC Bioinform 15:18. \n                    https:\/\/doi.org\/10.1186\/1471-2105-15-18","journal-title":"BMC Bioinform"},{"key":"4852_CR37","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders CT, Wong WSW, Swamy S, Becq J, Murray LJ, Cheetham RK (2012) Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28:1811\u20131817. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/bts271","journal-title":"Bioinformatics"},{"key":"4852_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fgene.2012.00035","volume":"3","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, Ruden DM, Lu X (2012) Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front Genet 3:35. \n                    https:\/\/doi.org\/10.3389\/fgene.2012.00035","journal-title":"Front Genet"},{"key":"4852_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:80\u201392. \n                    https:\/\/doi.org\/10.4161\/fly.19695","journal-title":"Fly (Austin)"},{"key":"4852_CR40","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45:D777\u2013D783. \n                    https:\/\/doi.org\/10.1093\/nar\/gkw1121","journal-title":"Nucleic Acids Res"},{"key":"4852_CR41","unstructured":"Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. Database of Single Nucleotide Polymorphisms (dbSNP). \n                    http:\/\/www.ncbi.nlm.nih.gov\/SNP\/"},{"issue":"7616","key":"4852_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O\u2019Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won H-H, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG, Consortium EA (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536(7616):285. \n                    https:\/\/doi.org\/10.1038\/nature19057","journal-title":"Nature"},{"key":"4852_CR43","doi-asserted-by":"publisher","first-page":"E2423-2429","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, Meyerson M, Getz G (2015) Oncotator: cancer variant annotation tool. Hum Mutat 36:E2423-2429. \n                    https:\/\/doi.org\/10.1002\/humu.22771","journal-title":"Hum Mutat"},{"key":"4852_CR44","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","volume":"32","author":"ZL Skidmore","year":"2016","unstructured":"Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, Griffith M (2016) GenVisR: genomic visualizations in R. Bioinformatics 32:3012\u20133014. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/btw325","journal-title":"Bioinformatics"},{"key":"4852_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13059-017-1193-3","volume":"18","author":"GO Silva","year":"2017","unstructured":"Silva GO, Siegel MB, Mose LE, Parker JS, Sun W, Perou CM, Chen M (2017) SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling. Genome Biol 18:66. \n                    https:\/\/doi.org\/10.1186\/s13059-017-1193-3","journal-title":"Genome Biol"},{"key":"4852_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4310\/SII.2016.v9.n1.a9","volume":"9","author":"A Ivanova","year":"2016","unstructured":"Ivanova A, Deal AM (2016) Two-stage design for phase II oncology trials with relaxed futility stopping. Stat Interface 9:93\u201398. \n                    https:\/\/doi.org\/10.4310\/SII.2016.v9.n1.a9","journal-title":"Stat Interface"},{"key":"4852_CR47","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0360-3016(00)00547-2","volume":"47","author":"LE Gaspar","year":"2000","unstructured":"Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001\u20131006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4852_CR48","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18:654\u2013662. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30109-2","journal-title":"Lancet Oncol"},{"key":"4852_CR49","doi-asserted-by":"publisher","first-page":"63110","DOI":"10.18632\/oncotarget.18668","volume":"8","author":"Y-C Huang","year":"2017","unstructured":"Huang Y-C, Lin S-J, Shih H-Y, Chou C-H, Chu H-H, Chiu C-C, Yuh C-H, Yeh T-H, Cheng Y-C (2017) Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. Oncotarget 8:63110\u201363120. \n                    https:\/\/doi.org\/10.18632\/oncotarget.18668","journal-title":"Oncotarget"},{"key":"4852_CR50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/dneu.22235","volume":"75","author":"Y-C Huang","year":"2015","unstructured":"Huang Y-C, Shih H-Y, Lin S-J, Chiu C-C, Ma T-L, Yeh T-H, Cheng Y-C (2015) The epigenetic factor Kmt2a\/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation. Dev Neurobiol 75:452\u2013462. \n                    https:\/\/doi.org\/10.1002\/dneu.22235","journal-title":"Dev Neurobiol"},{"key":"4852_CR51","doi-asserted-by":"publisher","first-page":"e52864","DOI":"10.1371\/journal.pone.0052864","volume":"7","author":"H Chen","year":"2012","unstructured":"Chen H, Sun B, Zhao Y, Song X, Fan W, Zhou K, Zhou L, Mao Y, Lu D (2012) Fine mapping of a region of chromosome 11q23.3 reveals independent locus associated with risk of glioma. PLoS ONE 7:e52864. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0052864","journal-title":"PLoS ONE"},{"key":"4852_CR52","doi-asserted-by":"publisher","first-page":"17367","DOI":"10.1038\/srep17367","volume":"5","author":"R Baskin","year":"2015","unstructured":"Baskin R, Woods NT, Mendoza-Fandi\u00f1o G, Forsyth P, Egan KM, Monteiro ANA (2015) Functional analysis of the 11q23.3 glioma susceptibility locus implicates PHLDB1 and DDX6 in glioma susceptibility. Sci Rep 5:17367. \n                    https:\/\/doi.org\/10.1038\/srep17367","journal-title":"Sci Rep"},{"key":"4852_CR53","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3892\/ijo.2016.3328","volume":"48","author":"YJ Cho","year":"2016","unstructured":"Cho YJ, Kang W, Kim SH, Sa JK, Kim N, Paddison PJ, Kim M, Joo KM, Hwang Y-I, Nam D-H (2016) Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma. Int J Oncol 48:1053\u20131062. \n                    https:\/\/doi.org\/10.3892\/ijo.2016.3328","journal-title":"Int J Oncol"},{"key":"4852_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jneuroim.2010.03.009","volume":"223","author":"N Weiss","year":"2010","unstructured":"Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van Evercooren A, Couraud P-O, Cazaubon S (2010) IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells. J Neuroimmunol 223:131\u2013134. \n                    https:\/\/doi.org\/10.1016\/j.jneuroim.2010.03.009","journal-title":"J Neuroimmunol"},{"key":"4852_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00401-007-0258-x","volume":"114","author":"A Brunn","year":"2007","unstructured":"Brunn A, Montesinos-Rongen M, Strack A, Reifenberger G, Mawrin C, Schaller C, Deckert M (2007) Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol (Berl) 114:271\u2013276. \n                    https:\/\/doi.org\/10.1007\/s00401-007-0258-x","journal-title":"Acta Neuropathol (Berl)"},{"key":"4852_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1194\/jlr.M700364-JLR200","volume":"49","author":"PT Tarr","year":"2008","unstructured":"Tarr PT, Edwards PA (2008) ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J Lipid Res 49:169\u2013182. \n                    https:\/\/doi.org\/10.1194\/jlr.M700364-JLR200","journal-title":"J Lipid Res"},{"key":"4852_CR57","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1471-4159.2007.05099.x","volume":"104","author":"WS Kim","year":"2008","unstructured":"Kim WS, Weickert CS, Garner B (2008) Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 104:1145\u20131166. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05099.x","journal-title":"J Neurochem"},{"key":"4852_CR58","doi-asserted-by":"publisher","first-page":"e0156516","DOI":"10.1371\/journal.pone.0156516","volume":"11","author":"Z Hegyi","year":"2016","unstructured":"Hegyi Z, Homolya L (2016) Functional cooperativity between ABCG4 and ABCG1 isoforms. PLoS ONE 11:e0156516. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0156516","journal-title":"PLoS ONE"},{"key":"4852_CR59","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.4049\/jimmunol.1700251","volume":"199","author":"MH Theus","year":"2017","unstructured":"Theus MH, Brickler T, Meza AL, Coutermarsh-Ott S, Hazy A, Gris D, Allen IC (2017) Loss of NLRX1 exacerbates neural tissue damage and NF-\u03baB signaling following brain injury. J Immunol 1950 199:3547\u20133558. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1700251","journal-title":"J Immunol"},{"key":"4852_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13041-014-0090-x","volume":"7","author":"E Imbeault","year":"2014","unstructured":"Imbeault E, Mahvelati TM, Braun R, Gris P, Gris D (2014) Nlrx1 regulates neuronal cell death. Mol Brain 7:90. \n                    https:\/\/doi.org\/10.1186\/s13041-014-0090-x","journal-title":"Mol Brain"},{"issue":"1","key":"4852_CR61","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clbc.2017.07.017","volume":"18","author":"L Mounsey","year":"2016","unstructured":"Mounsey L, Deal AM, Benbow JM, Keith K, Zagar TM, Dees EC, Carey LA, Ewend M, Anders CK (2016) A changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new, targeted therapies. Clin Breast Cancer 18(1):29\u201337","journal-title":"Clin Breast Cancer"},{"key":"4852_CR62","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/cncr.30616","volume":"123","author":"JA Miller","year":"2017","unstructured":"Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH (2017) Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 123:2283\u20132293. \n                    https:\/\/doi.org\/10.1002\/cncr.30616","journal-title":"Cancer"},{"key":"4852_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2016.12.015","volume":"74","author":"JP Leone","year":"2017","unstructured":"Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA, Vallejo CT (2017) Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur J Cancer 74:17\u201325. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.12.015","journal-title":"Eur J Cancer"},{"key":"4852_CR64","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870\u2013884. \n                    https:\/\/doi.org\/10.1007\/s12325-013-0060-1","journal-title":"Adv Ther"},{"key":"4852_CR65","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/bjc.2011.464","volume":"106","author":"C Lo Nigro","year":"2012","unstructured":"Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T (2012) High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer 106:397\u2013404. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.464","journal-title":"Br J Cancer"},{"key":"4852_CR66","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/path.4583","volume":"237","author":"JM Saunus","year":"2015","unstructured":"Saunus JM, Quinn MC, Patch A-M, Pearson JV, Bailey PJ, Nones K, McCart Reed AE, Miller D, Wilson PJ, Al-Ejeh F, Mariasegaram M, Lau Q, Withers T, Jeffree RL, Reid LE, Da Silva L, Matsika A, Niland CM, Cummings MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Anderson MJ, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Taylor D, Waddell N, Wood S, Xu Q, Kassahn KS, Narayanan V, Taib NA, Teo S-H, Chow YP, kConFab, Jat PS, Brandner S, Flanagan AM, Khanna KK, Chenevix-Trench G, Grimmond SM, Simpson PT, Waddell N, Lakhani SR (2015) Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol 237:363\u2013378. \n                    https:\/\/doi.org\/10.1002\/path.4583","journal-title":"J Pathol"},{"key":"4852_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5630","author":"N Priedigkeit","year":"2016","unstructured":"Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV (2016) Intrinsic subtype switching and acquired ERBB2\/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.5630","journal-title":"JAMA Oncol"},{"key":"4852_CR68","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164\u20131177. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0369","journal-title":"Cancer Discov"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4852-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:08:46Z","timestamp":1589720926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4852-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4852"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4852-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"4 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Carey K. Anders is an uncompensated consultant\/advisory board member for Novartis, Sanofi, toBBB, Angiochem, Merrimack, Lily, Genentech, Nektar, and Kadmon, receives unrelated research funding from Novartis, Sanofi, toBBB, Angiochem, Merrimack, PUMA, Lily, Merck, Oncothyreon, Cascadian, Nektar, and Tesaro, and receives honoraria for UptoDate and Jones and Bartlett Publishing. Rita Nanda is a consultant\/advisory board member for AstraZeneca, Celgene, Genentech, Merck, Pfizer, Puma, and Syndax. Nikita Shah is a consultant for Novartis. The other authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript complies with all current laws of the country in which they were performed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained by all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}